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Abstract
AIM: To determine whether aspirin or non-aspirin non-
steroidal anti-inflammatory drugs (NA-NSAIDs) prevent 
colorectal cancer (CRC) in patients with inflammatory 
bowel disease (IBD).
METHODS: We performed a systematic review and 
meta-analysis. We searched for articles reporting the 
risk of CRC in patients with IBD related to aspirin or NA-
NSAID use. Pooled odds ratios (OR) and 95%CIs were 
determined using a random-effects model. Publication 
bias was assessed using Funnel plots and Egger’s test. 
Heterogeneity was assessed using Cochran’s Q and the 
I 2 statistic.
RESULTS: Eight studies involving 14917 patients and 
3 studies involving 1282 patients provided data on the 
risk of CRC in patients with IBD taking NA-NSAIDs and 
aspirin respectively. The pooled OR of developing CRC 
after exposure to NA-NSAIDs in patients with IBD was 
0.80 (95%CI: 0.39-1.21) and after exposure to aspirin 
it was 0.66 (95%CI: 0.06-1.39). There was significant 
heterogeneity (I 2 > 50%) between the studies. There 
was no change in the effect estimates on subgroup 
analyses of the population studied or whether 
adjustment or matching was performed.
CONCLUSION: There is a lack of high quality evidence 
on this important clinical topic. From the available 
evidence NA-NSAID or aspirin use does not appear to 
be chemopreventative for CRC in patients with IBD. 
META-ANALYSIS
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Core tip: Colorectal cancer (CRC) remains a serious 
complication of inflammatory bowel disease (IBD) 
and chemoprevention is an attractive alternative to 
prophylactic surgery or intensive surveillance programs. 
Aspirin and non-steroidal anti-inflammatory drugs have 
chemopreventative activity against “sporadic” CRC. We 
have synthesized the available data for the prevention 
of IBD associated CRC and found no potential protective 
effect for either medication. There is a lack of available 
data on the potential effects of these medications in 
preventing CRC in patients with IBD and there is a need 
for high quality, focused studies on this topic.
Burr NE, Hull MA, Subramanian V. Does aspirin or non-aspirin 
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INTRODUCTION
One of the most serious complications of inflammatory 
bowel disease (IBD) is the development of colorectal 
cancer (CRC). Worldwide, the risk of developing CRC 
ranges between 5-40/100000 people depending 
on location, with a marked increase in Western 
populations[1,2], this is increased to 300/100000 in 
patients with longstanding ulcerative colitis (UC)[3]. The 
cumulative probability of developing CRC in patients 
with UC increases from 2%, 8% and 18% after 10, 
20 and 30 years of disease respectively[3]. In patients 
with CD, a meta-analysis of population-based studies 
has demonstrated an increased risk of CRC, with a 
standardized incidence ratio of 1.9 (95%CI: 1.4-2.5)[4]. 
Whilst the risk of CRC in CD appears to be stable, a 
recent study from Denmark[5] has reported a decrease 
in CRC incidence in patients with UC over the past 
30 years. It is currently unclear why there may be a 
reduction in incidence, but a plausible hypothesis is 
that increased use of IBD medications may reduce 
inflammation-driven colorectal carcinogenesis. 
Identified risk factors for developing CRC in patients 
with IBD include primary sclerosing cholangitis[6], 
degree of inflammation[7-9], duration of disease, 
extent of colonic involvement[10], as well as family 
history of colorectal cancer[10,11]. International society 
guidelines advocate regular surveillance colonoscopy 
examinations to identify malignant and pre-malignant 
lesions[12]. These are resource intensive and not 
without risk. As such primary prevention of CRC in 
these patients is an attractive alternative. Several 
treatment modalities have been proposed as potential 
chemopreventative agents and studied mainly via 
retrospective case-control and cohort studies[13]. 
These include 5-aminosalicylic acid preparations[14-16], 
ursodeoxycholic acid (in patients with concomitant 
PSC)[17,18], thiopurine analogues[19], aspirin and non-
aspirin non-steroidal anti-inflammatory drugs (NA-
NSAIDs), and statins[20]. 
There are plausible biological mechanisms for 
how NA-NSAIDs, and aspirin, may prevent CRC 
development in patients with IBD. In epidemiological, 
laboratory and clinical studies aspirin has consistently 
been shown to reduce the incidence of several tumors, 
including “sporadic” CRC not related to a defined 
genetic predisposition or IBD[21]. The exact anti-
neoplastic mechanism(s) of aspirin and NA-NSAIDs is 
not yet clear but several cell signaling pathways have 
been implicated as targets for COX-dependent and 
COX-independent mechanisms of action[22,23]. Aspirin 
use also appears to prevent CRC metastasis, as well as 
the risk of primary CRC[24].
As well as the potential benefits for chemoprevention 
there are concerns about negative effects of aspirin 
and the NA-NSAIDs on the lower gastrointestinal 
tract. Adverse effects of NA-NSAIDs on the colon 
include a NSAID colonopathy with diaphragm-like 
stricturing and mucosal inflammation and ulceration, 
complicated diverticular disease including bleeding[25], 
and microscopic colitis[26,27]. A possible association 
between the use of NSAIDs including aspirin and the 
onset or relapse of IBD has been repeatedly suggested. 
However, lack of controlled prospective trials make it 
difficult to draw definite conclusions[28,29]. 
Aspirin use is associated with several side effects. 
The main concern is the risk of upper gastrointestinal 
bleeding and hemorrhagic stroke. Most studies using 
aspirin have not shown increased death rates from 
gastrointestinal bleeding suggesting that any bleeds 
related to aspirin are small and relatively insignificant[30]. 
There are currently conflicting data on the putative 
role of NA-NSAIDs and aspirin in the prevention of CRC 
in IBD. We therefore performed a systematic review and 
meta-analysis in order to identify if there is evidence 
that aspirin and NA-NSAIDs have chemopreventative 
activity against CRC in patients with IBD.
MATERIALS AND METHODS
We followed a pre-specified and peer-reviewed 
protocol; the PRISMA statement, a 27 item checklist 
deemed essential for reporting systematic reviews 
and meta-analyses of randomized controlled trials and 
observational studies[31].
Search strategy
We searched multiple electronic databases including 
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MEDLINE (1965 to July 2015), EMBASE (1974 to 
July 2015), ISI Web of Science (1945-July 2015) and 
the Cochrane Register of Controlled Trials. The MeSH 
search terms included were Inflammatory Bowel 
Disease AND CRC AND Aspirin OR NSAIDs. Free text 
terms and variations were used. No limits or language 
restrictions were applied. We performed a recursive 
search of the bibliographies of relevant review articles 
and of the included studies. Articles were assessed by 
two independent reviews (Burr NE and Subramanian 
V) to assess eligibility for inclusion. Any disagreements 
were resolved by consensus decision.
Study selection
Studies were eligible for inclusion if they reported on 
risk of developing CRC in patients with IBD on either 
NA-NSAIDs or aspirin compared to a control population. 
Studies published only in abstract form were not 
included. Two reviewers (Burr NE and Subramanian V) 
independently screened titles and abstracts identified by 
the preliminary searches to identity potentially eligible 
studies. Both reviewers independently assessed the full 
text articles of potentially relevant studies for inclusion 
in the pooled analysis. Data from included studies were 
independently extracted by two investigators (Burr NE 
and Subramanian V). Information was collected on 
characteristics of the study (population studied, country 
of origin, study design, definition of drug exposure) 
and medication use including NA-NSAIDs, aspirin and 
development of CRC. Agreement between the reviewers 
was greater than 95% and differences between the 
datasets were resolved by consensus decision.
Statistical analysis
The odds ratio (OR) with 95% confidence interval (CI) 
of developing CRC in patients with IBD on aspirin or 
NA-NSAIDs compared with controls was extracted 
from the study. When insufficient (no information on 
odds ratio or drug exposure) data had been published, 
we contacted the study authors. As randomization 
and blinding is not possible in observational studies 
and baseline differences between the groups can 
confound the results we used the authors’ ORs with 
adjustment for potential confounding factors wherever 
available. The pooled OR estimate was calculated from 
an inverse-variance-weighted average of the individual 
studies[32]. A DerSimonian-Laird random effects model 
was used a priori[33]. As a further sensitivity analysis 
a fixed effects model was used for comparison. Stata 
version 12 (StataCorp, College Station, Texas, United 
States), was used for all of the data analysis. 
We used the Cochran’s Q statistic to test hete-
rogeneity among pooled estimates[34]. Statistical 
heterogeneity was also measured by the I2 statistic, 
which quantifies the proportion of inconsistency 
in individual studies that cannot be explained by 
chance[35]. Values of I2 equal to 25%, 50%, and 75% 
represent low, moderate, and high heterogeneity, 
respectively. To test for publication bias, we used a test 
for asymmetry of the funnel plot proposed by Egger 
et al[36]. This test detects funnel plot asymmetry by 
determining whether the intercept deviates significantly 
from zero in a regression of the normalized effect 
estimate (estimate divided by the standard error) 
against precision (reciprocal of the standard error of the 
estimate) weighted by the reciprocal of the variance of 
the estimate. 
The quality of the primary studies assessing the risk 
of bias was evaluated using the Newcastle-Ottawa Scale 
for non-randomized studies (NOS)[37]. Studies score for 
a maximum of 4 for selection, 2 for comparability and 3 
for outcomes (cohort) or exposures (case-control). We 
regarded scores of 0-3 as low, 4-6 as medium and 7-9 
as high methodological quality. 
We performed pre-planned subgroup analyses to 
assess the following factors on the trial outcome and 
on the heterogeneity of the analyses: (1) matching or 
adjustment for confounders (any or none); and (2) the 
population studied (population-based or other).
RESULTS
Our searches retrieved 9 potentially relevant articles, 
of which 3[14,38,39] provided data on aspirin exposure 
and risk of CRC and 8[14,39-45] on NA-NSAID exposure 
and risk of CRC in patients with IBD. Figure 1 outlines 
the fate of the selected articles. The studies were 
either retrospective case-control, nested case-control 
or cohort studies by design and 5[14,40-42,44] included 
population-based analysis. Table 1 lists all the included 
studies and their characteristics. We contacted authors 
of papers for missing data but did not obtain any extra 
information. The quality assessment of the studies 
using the Newcastle Ottawa scale is also detailed in 
Table 1. Only 3 studies[39,41,42] provided multivariate 
analysis of data for risk of developing CRC in IBD 
patients exposed to aspirin or NA-NSAIDs. 
Cumulative risk of developing CRC in IBD patients 
exposed to NA-NSAIDs
Eight studies, including 14917 patients with IBD 
provided data on the risk of developing CRC after 
exposure to NA-NSAIDs. Using a random effects 
model, the pooled adjusted OR of developing CRC after 
exposure to NA-NSAIDs in patients with IBD was 0.80 
(95%CI: 0.39-1.21) (Figure 2). The heterogeneity 
between the studies was high (Cochran’s Q = 38.15, P 
= 0.00 and I2 = 81.6%). 
Sensitivity analysis and publication bias
Pre-planned subgroup analyses showed that there 
was no difference in the overall effect estimate 
when comparing the population studied or whe-
ther adjustment or matching for confounders was 
performed (Table 2). There was no heterogeneity 
among population-based studies (Cochran’s Q = 2.39, 
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Table 1  Characteristics of studies included in the analysis
Author Design Population Definition of 
IBD
Drug 
exposure
Exclusion 
criteria
No. of 
patients
OR (95%CI)1 Adjustment/
matching
NOS quality 
assessment
Bansal et al[42], 
1996
Case-control US veterans 
affairs
Clinical 
database
NSAID 
associated 
diagnosis
Not specified 11446 0.84 (0.65-1.09) Adjusted for 
age, sex and 
ethnicity
6
Eaden et al[38], 
2000
Case-control UK Hospital Clinical, 
pathological 
and 
radiological 
records
Prescribed 
5-10 years 
before 
diagnosis
Colorectal 
surgery, IBD 
diagnosed at 
time of cancer 
diagnosis
    206 0.80 (0.21-2.98) 
Aspirin
Non-adjusted 4
Van Staal 
et al[14], 2005
Nested case-
control
UK general 
practice
Clinical 
records
Prescribed in 
the 6 mo prior 
to diagnosis
Colorectal 
surgery, previous 
history of CRC
    700 1.52 (0.7-3.25) 
(Aspirin)
Non-adjusted 5
0.80 (0.38-1.66) 
(NA-NSAID’s)
Velayos et al[39], 
2006
Case-control US Hospital Clinical, 
pathological 
and 
endoscopic 
records
2 records of 
use in notes
Previous CRC, 
IBD diagnosed 
at same time as 
CRC, incomplete 
data
    376 0.3 (0.1-0.8) 
(Aspirin)
Matched 
on gender, 
duration of 
disease and 
extent of 
disease
8
0.1 (0.03-0.5) 
(NA-NSAID)
Terdiman 
et al[40], 2007
Case-control US insurance 
claims
Clinical 
records
Prescribed in 
the year before 
diagnosis
Colorectal 
surgery
  1536 0.97 (0.74-1.28) Non-adjusted 5
Tang et al[43], 
2010
Retrospective 
cohort
US Hospital Clinical 
database
Ever used No colonic 
involvement of 
IBD
      48 0.29 (0.03-2.75) Non-adjusted 5
Samadder 
et al[41], 2011
Case-control N. Israel 
community
Patient 
questionnaires
Weekly for > 
3 yr
Previous history 
of CRC
      60 0.49 (0.07-3.32) Matched for 
age, gender 
and ethnicity
6
Baars et al[44], 
2011
Case-control Netherlands 
nationwide 
pathology
Pathology 
reports
Ever used IBD diagnosed at 
the same time as 
CRC
    551 1.96 (0.72-5.36) Non-adjusted 6
Rubin et al[45], 
2013
Case-control US Hospital Pathology 
reports
Not specified Incomplete 
records
    200 1.84 (0.75-2.5) Non-adjusted 5
1OR for colorectal cancer (CRC) chemoprotective effect of non-aspirin non-steroidal (NA-NSAID) use in patients in inflammatory bowel disease (IBD) 
unless otherwise stated. For cohort studies was used only for the Tang et al[43] study. The scale for case-control studies was used for the other studies. NOS: 
Newcastle-Ottawa Score. 
Figure 1  Flow chart showing the results from the search strategy. NA-NSAIDs: Non-aspirin non-steroidal anti-inflammatory drugs.
Unique articles included in the analyses - 9
 Data on NA-NSAIDs - 6
 Data on aspirin - 1
 Data on both medications - 2
Full text articles excluded - 32
1 article included 
from recursive 
search
50 unique articles remaining
Excluded after screening title 
and abstract - 458
508 unique articles 
identified from database 
search
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P = 0.79 and I2 = 0%) but high heterogeneity between 
hospital-based studies (Cochran’s Q = 14.17, P < 
0.005 and I2 = 92%)). There was some funnel plot 
asymmetry compatible with publication bias (Figure 3). 
However Egger’s regression asymmetry test was non-
significant (P = 0.56). The regression asymmetry test 
is probably underpowered as there are only 8 studies 
included in this meta-analysis[46]. 
Cumulative risk of developing CRC in IBD patients 
exposed to aspirin
Three studies, including 1282 patients with IBD, 
provided data on risks of developing CRC after 
exposure to aspirin. The pooled adjusted OR of 
developing CRC after exposure to aspirin in patients 
with IBD was 0.66 (95%CI: 0.06-1.39) (Figure 2). 
A random effects model was chosen a priori. The 
heterogeneity between the studies was high (Cochran’
s Q = 0.166. and I2 = 44.4%). A fixed effects model 
was performed as a sensitivity test which changed the 
pooled adjusted OR to 0.41 (95%CI: 0.08-0.74). We 
did not attempt to do an analysis of publication bias 
or subgroup analyses as there were only 3 studies 
included in the final analysis.
DISCUSSION
We present the first systematic review and meta-
analysis of the effects of NA-NSAIDs and aspirin for CRC 
chemoprevention in patients with IBD to our knowledge. 
It is important to synthesize the available literature on 
this subject as CRC remains an important complication 
of IBD and NA-NSAIDs including aspirin have been 
consistently shown to have a protective effect in 
sporadic colorectal cancer[47,48]. We found 9 retrospective 
studies fitting the inclusion criteria, but unfortunately 
there have been no prospective randomized trials. 
Study %
ID ES (95%CI) Weight
NA-NSAID
Bansal (1996) 0.84 (0.65, 1.09)   16.11
Van Staal (2005) 0.80 (0.38, 1.66)   10.64
Velayos (2006) 0.10 (0.03, 0.50)   15.95
Terdiman (2007) 0.97 (0.74, 1.28)   15.56
Tang (2010) 0.29 (0.03, 2.75)     4.52
Sammader (2011) 0.49 (0.07, 3.32)     3.44
Baars (2011) 1.96 (0.72, 5.36)     1.87
Rubin (2013) 1.84 (0.75, 2.50)     7.97
Subtotal (I 2 = 81.6%, P  = 0.000) 0.80 (0.39, 1.21)   76.07
Aspirin
Eaden (2000) 0.80 (0.21, 2.98)     4.40
Van Staal (2005) 1.52 (0.70, 3.25)     4.96
Velayos (2006) 0.30 (0.10, 0.80)   14.57
Subtotal (I 2 = 44.4%, P  = 0.166)  0.66 (-0.06, 1.39)   23.93
Overall (I 2 = 77.1%, P  = 0.000) 0.76 (0.42, 1.09) 100.00
NOTE: Weights are from random effects analysis
                                   0 0.5  1            2.5
Medication reduces risk of CRC medication increases risk of CRC
Figure 2  Forest plot of odds ratios and 95%CI for effect of non-aspirin non-steroids anti-inflammatory drugs or aspirin on colorectal cancer development 
in patients with inflammatory bowel disease. Random effects model.
Table 2  Subgroup analyses for studies reporting on risk of 
colorectal cancer in patients with inflammatory bowel disease 
taking non-aspirin non-steroidal anti-inflammatory drugs 
No. of studies Pooled OR (95%CI)
Matched y/n 
   Matched/adjusted 3 0.47 (0.18-1.13)
   None 5 1.04 (0.65-1.43)
Study location
   Hospital 6 0.92 (0.78-2.62)
   Population 2 0.88 (0.72-1.04)
0.0
0.5
1.0
1.5
2.0
-3           -2             -1            0             1             2            3
                                  Log odds ratio
St
an
da
rd
 e
rr
or
Funnel plot of standard error by log odds ratio
Figure 3  Funnel plot for publication bias for studies looking at the odds 
ratio of developing colorectal cancer in patients with inflammatory bowel 
disease on non-aspirin non-steroids anti-inflammatory drugs.
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There were only 3 studies that reported on aspirin use 
in patients with IBD associated cancer. We found no 
significant potential protective effect for NA-NSAIDs or 
aspirin against the development of CRC in IBD patients.
There are several limitations to this meta-analysis. 
All the included studies are retrospective and are 
therefore subject to inherent biases and confounding. 
Publication bias is another possible limitation as 
negative studies are less likely to be published and 
therefore not included in the analyses. However we 
have attempted to reduce the possibility of publication 
bias by conducting an exhaustive search of the 
literature and did not limit inclusion of studies based on 
language. Most of the studies included in our analysis 
reported NA-NSAID and aspirin use as a secondary 
outcome measure and results from a multivariate 
analysis was provided only by 3 studies[39,41,42]. The 
study with the most robust methodology from Velayos 
et al[39] reported a significant chemopreventative 
role for both NA-NSAIDs and aspirin. There were 
differences in the studies related to the definition of 
drug exposure and as these studies were all retro-
spective it was not possible to check compliance with 
the medication. A further limitation with studies of 
this type is confounding by indication. Aspirin and NA-
NSAID use could be associated with another factor, 
such as another medical condition, that is associated 
with colorectal cancer. It is not possible to adjust or 
correct for all such factors so this always must be born 
in mind when interpreting such studies.
The dose and duration of medication exposure was 
not consistently recorded. An important consideration 
of chemoprevention against colorectal cancer is the 
duration of exposure to the medication. In the evidence 
for aspirin protecting against sporadic CRC a duration 
of > 5 years conferred a 34% reduction in CRC risk[49]. 
The only study included here which took this into 
consideration was Eaden et al[38] where a prescription 
in the preceding 5-10 years before diagnosis was 
required for inclusion as positive exposure (Table 1). 
The dose of aspirin used was not stated in most of the 
studies but it is likely to have been low dose as used in 
routine clinical practice in patients with cardiovascular 
risk factors, 75 mg in the United Kingdom and 81 
mg in the United States. It is possible that a higher 
dose may be needed for chemoprevention of colitis-
associated CRC. For example, a recent trial in patients 
with Lynch syndrome, a hereditary condition associated 
with high risk of CRC, demonstrated that high dose (600 
mg daily) aspirin conferred protection against CRC[50]. 
Little information was provided about the timing and 
duration of exposure to aspirin and NA-NSAID’s in any 
of the included studies. Aspirin and NA-NSAIDs may 
be unable to prevent the progression from dysplasia 
to cancer and could therefore be chemopreventative 
only in those with exposure to the drug from soon 
after onset of IBD and those with longer duration of 
exposure to the medication. Unfortunately none of 
the studies included in this meta-analysis provided 
data on the timing of exposure to NA-NSAID/aspirin 
and duration of IBD, to determine if early or long-
term exposure was chemopreventative. The main 
outcome of interest was the development of CRC and 
not dysplasia which could support the argument that 
in some of the patients, CRC may have developed in 
those exposed to aspirin or NA-NSAIDs only after they 
had already developed colorectal neoplasia. 
Adverse effects of NSAIDs on the gastrointestinal 
tract need to be considered in future studies as there 
is a potential increased incidence of disease flares 
with the use of NSAIDs, including aspirin[51]. This 
issue is still under debate as NSAIDs are often used 
for treatment of arthralgia and abdominal pain and it 
may be that NSAIDs are used after the flare develops 
rather than being the potential cause of the flare. 
Colorectal cancer remains a serious complication 
of IBD. Current methods to reduce CRC in IBD are 
the use of colonoscopic surveillance or by prophylactic 
proctocolectomy. British Society of Gastroenterology 
guidelines advocate screening and surveillance 
colonoscopy which can result in annual tests for high 
risk patients[52]. Chemoprevention is therefore an 
attractive proposition for these patients. NA-NSAIDs 
and aspirin remain biologically plausible targets for 
chemoprevention in IBD. As we have shown the clinical 
evidence is limited. The available data is hampered as 
most of the studies include small numbers of patients 
and do not include adequate information on medication 
dose and duration. Potential chemoprevention agents 
are likely to take several years to display a protective 
effect as in the sporadic CRC population and this 
should be borne in mind in future studies. Prospective 
randomized chemoprevention trials are unlikely to be 
done as the sample size required would be too large 
and therefore well-conducted epidemiological studies 
using prospective databases are needed to clarify the 
true effect of aspirin and/or NA-NSAIDs on the risk of 
CRC in patients with IBD. 
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available evidence there is no data to support the use of these medications in 
chemoprevention against colorectal cancer but the study has highlighted the 
lack of high quality data.
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The study highlights the need for focused studies into the potential protective 
effect of these medications.
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This systematic review and meta-analysis gives useful information to clinicians 
and patients on the role of these medications. It highlights the lack of data in 
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